Onconic Therapeutics
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Onconic Therapeutics is a Korea-based research-driven biopharmaceutical company dedicated to developing innovative therapeutics in oncology and gastrointestinal diseases. Our mission is to deliver differentiated medicines that address unmet medical needs and improve patient outcomes worldwide.
Pipeline Highlights
Nesuparib (JPI-547) is a next-generation dual PARP/Tankyrase inhibitor designed to overcome key limitations of conventional PARP inhibitors.
* Expands therapeutic potential beyond BRCA/HRD-positive populations through dual-targeting synergy across broader tumor types
* Clinically demonstrated safety and encouraging efficacy, with ongoing Phase 2 programs in pancreatic, endometrial, gastric, and ovarian cancers
* Significant commercial potential with an estimated market opportunity of up to USD 4.3B by 2034
* Differentiated and de-risked asset with versatile combination potential, including immunotherapy
Seeking out-licensing and co-development partners.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2020
Lead Product in Development:
Nesuparib (JPI-547)
CEO
John Kim
Development Phase of Lead Product
Phase II
Exchange
KOSDAQ
Ticker
476060
When you expect your next catalyst update?
End of May 2026 (ASCO presentation of Nesuparib Phase 1b data)
June 2026 (out-licensing transactions)
What is your next catalyst (value inflection) update?
Key upcoming catalysts include ASCO presentation of Nesuparib Phase 1b data, continued expansion of Phase 2 oncology studies, and potential regional out-licensing transactions for GI assets, including Zastaprazan (JP-1366)
Primary Speaker
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}